Hints and tips:
...While not seen in Germany before, Braas’s tactic has some similarities to that deployed by French drugmaker Aventis in 2004, in an attempt to avoid being acquired by Sanofi in a $60bn deal....
...Sanofi and Aventis merged to take on US pharma, but have not caught Pfizer. Nor have Glaxo and SmithKline Beecham....
...Expansion by larger drug companies was the norm at the start of this century, from the merger that created GlaxoSmithKline in 2000 and the $67bn purchase of Aventis by Sanofi in 2004, to Pfizer’s $68bn paid...
...Amgen, Sanofi-Aventis and Pfizer have all made acquisitions in this area in Brazil....
...Mr Soriot, 53, a Frenchman who trained as a veterinary surgeon before obtaining an MBA, worked for much of his career in Asia for Roussel Uclaf, Hoechst and Aventis, which became part of Sanofi in 2004....
...It was the largest bond sale in the US since March 2011, when Sanofi-Aventis sold $7bn, Dealogic said....
...That is good news for the backlog of other companies awaiting similar appeals, including brewer SABMiller, US wireless operator AT&T, and French drugmaker Sanofi-Aventis....
...Shire had little incentive to fund the extra tests as production at Genzyme, now owned by Sanofi-Aventis, would return to normal later this year, analysts said....
...He also has served on the board of Genzyme, the biotech company sold to Sanofi-Aventis this year for more than $20bn....
...For example, Sanofi-Aventis, the French multinational pharmaceutical company, is using Microsoft’s SharePoint to revamp its R&D process....
...The action follows the arrests last year in Belgrade of senior officials at the Serbian Institute for Oncology and Radiology, as well as the heads of the Belgrade offices of AstraZeneca, Roche, Actavis, Sanofi-Aventis...
...Sanofi-Aventis plans to cut costs and expand its animal health business through acquisitions as it fully integrates Merial after the collapse of its longstanding joint venture with Merck of the US....
...Merck has recently changed chief executive, appointing Ken Frazier in a move that has sparked a reassessment of strategy by the US drugmaker, which retains a joint venture with Sanofi-Aventis for human vaccines...
...Sanofi-Aventis brought an end to its protracted pursuit of Genzyme with an agreed $20.1bn cash takeover of the US biotech company, coupled with additional conditional payments over the next decade, reports...
...Sanofi-Aventis cautioned that 2011 earnings were likely to be down by as much as 10 per cent from last year’s €7.06 ($9.68) a share as a result of increased pricing pressure and threats from generic competition...
...Investors have placed a significant discount on future conditional payments offered by Sanofi-Aventis as part of its $20bn takeover of Genzyme, the US biotech business, announced on Wednesday....
...Merck maintains a development and marketing partnership for vaccines in Europe with Sanofi-Aventis, and until the recent collapse of talks it was planning a renewal of Merial, its long-standing partnership...
...News came on Wednesday morning that Sanofi-Aventis has finally clinched its deal to buy Genzyme after raising its offer to $20.1bn for the US biotech business....
...The CVR helped Sanofi-Aventis win its takeover bid, providing a way around protracted disagreements between Sanofi-Aventis and Genzyme that centred on the value of the US biotech group’s experimental drug...
...The deals this week included some large transactions to finance acquisitions, such as the $7bn sold by Sanofi-Aventis....
...Sanofi-Aventis has continued aggressively to acquire others, including ultimately winning support for the takeover of US group Genzyme after raising its bid above $20bn....
...Many, including Pfizer, GlaxoSmithKline and Sanofi-Aventis, are reducing research spending and closing therapy units, with the aim of boosting productivity....
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...Investors were also awaiting the announcement of a takeover of Genzyme , the US pharmaceuticals company, by its French competitor Sanofi-Aventis....
International Edition